XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.22.1

License Agreements - Additional Information (Details) - USD ($) |  | 1 Months Ended | 3 Months Ended |  |
--- | --- | --- | --- | --- | ---
Mar. 28, 2022 | Apr. 30, 2022 | Dec. 31, 2020 | Apr. 30, 2020 | Mar. 31, 2022 | Mar. 31, 2021 | Jan. 31, 2022 | Jan. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | $ 20,071,000 | $ 32,774,000 |  |
Proceeds from stock options exercised |  |  |  |  | 176,000 |  |  |
Pfizer License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  |  | 25,000,000.0 |  |
Milestone and royalties incurred |  |  |  |  | 0 |  |  |
Upfront payments |  |  |  |  |  | $ 5,000,000.0 |  |
Pfizer License Agreement | Series B Convertible Preferred Stock |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Issuance of convertible preferred stock shares |  |  |  |  |  | 12,152,145 |  |
Issuance of convertible preferred stock value |  |  |  |  |  | $ 20,000,000.0 |  | $ 20,000,000.0
Pfizer License Agreement | Research and Development Expenses |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Payment for license fee |  |  |  |  |  | 25,000,000.0 |  |
LegoChem License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Payments to purchase licensed products |  |  |  |  |  | 9,000,000.0 |  |
Proceeds from stock options exercised |  |  | $ 8,000,000.0 |  |  |  |  |
Extra milestone payment |  |  | $ 9,600,000 |  |  |  |  |
Derivative liability |  |  |  |  |  | 3,400,000 | $ 9,600,000 | $ 3,400,000
Fair value adjustment to the derivative liability |  |  |  |  |  | $ 1,100,000 |  |
Other milestone and royalties incurred |  |  |  |  | 0 |  |  |
Biosion License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | 10,000,000 |  |  |
Milestone and royalties incurred |  |  |  |  | $ 0 |  |  |
Royalty obligation period for licensed products upon first commercial sale | 12 years |  |  |  |  |  |  |
Biosion License Agreement | Subsequent Event |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Upfront fee |  | $ 10,000,000 |  |  |  |  |  |
Aggregate maximum obligation to pay future contingent milestone payments for normal approval |  | 217,500,000 |  |  |  |  |  |
Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval |  | $ 222,500,000 |  |  |  |  |  |
University License Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Stock issued |  |  |  | 48,919 |  |  |  |
Milestone and royalties incurred |  |  |  |  |  |  | $ 0 |

X
- Definition Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval. + References No definition available. + Details
Name: | pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForAcceleratedApproval
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate maximum obligation to pay future contingent milestone payments for normal approval. + References No definition available. + Details
Name: | pyxs_AggregateMaximumObligationToPayFutureContingentMilestonePaymentsForNormalApproval
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Convertible preferred stock shares issued value. + References No definition available. + Details
Name: | pyxs_ConvertiblePreferredStockSharesIssuedValue
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Extra milestone payment. + References No definition available. + Details
Name: | pyxs_ExtraMilestonePayment
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Issuance of convertible preferred stock shares. + References No definition available. + Details
Name: | pyxs_IssuanceOfConvertiblePreferredStockShares
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone and royalties incurred. + References No definition available. + Details
Name: | pyxs_MilestoneAndRoyaltiesIncurred
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Other milestone and royalties incurred. + References No definition available. + Details
Name: | pyxs_OtherMilestoneAndRoyaltiesIncurred
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payment for license fee. + References No definition available. + Details
Name: | pyxs_PaymentForLicenseFee
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty obligation period for licensed products upon first commercial sale. + References No definition available. + Details
Name: | pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
Namespace Prefix: | pyxs_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee. + References No definition available. + Details
Name: | pyxs_UpfrontFee
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payments. + References No definition available. + Details
Name: | pyxs_UpfrontPayments
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313 + Details
Name: | us-gaap_DerivativeLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties. + References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueAdjustment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash inflow from exercise of option under share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromStockOptionsExercised
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_BiosionLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |